Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Early-onset colorectal cancer demands a new research playbook

Colorectal cancer is no longer a disease confined to older adults.

March 20, 2026

KU Cancer Center deploys new mobile cancer screening bus

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society.

March 06, 2026

Vol.52 No.09

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Podcast

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical Health Equity

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

January 16, 2026

Vol.52 No.02

By Sara Willa Ernst

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

YOU MAY BE INTERESTED IN

Early-onset colorectal cancer demands a new research playbook

KU Cancer Center deploys new mobile cancer screening bus

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

With five-year cancer survival at an all-time high, does this mean people are living longer?

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

Renew today!

Subscriber content

Never miss an issue!

Login